Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Arcus Biosciences, Inc. (RCUS)
|
Add to portfolio |
|
|
|
| Price: |
$40.29
| | Metrics |
| OS: |
74.5
|
M
| |
|
|
| Market cap: |
$3
|
B
| |
|
|
|
Net cash:
|
$1.01
|
B
| |
$13.56
|
per share
|
|
EV:
|
$1.99
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($338)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 112.0 | 383.0 | 78.0 | 15.0 | 8.4 | 1.4 | 0.0 |
| Revenue growth | -70.8% | 391.0% | 420.0% | 79.6% | 491.2% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 112.0 | 383.0 | 78.0 | 15.0 | 8.4 | 1.4 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 392.0 | 329.0 | 202.0 | | | | |
| Research and development | | | | 78.5 | 49.6 | 47.2 | 14.2 |
| General and administrative | | | | 25.2 | 13.6 | 7.6 | 3.9 |
| EBIT | -246.0 | 56.0 | -122.0 | -89.9 | -55.7 | -53.9 | -18.2 |
| EBIT margin | -219.6% | 14.6% | -156.4% | -599.4% | -667.4% | -3811.5% | |
| Pre-tax income | -266.0 | 55.0 | -123.0 | -84.7 | -49.6 | -53.1 | -18.0 |
| Income taxes | 1.0 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 3.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -267.0 | 53.0 | -123.0 | -84.7 | -49.6 | -53.1 | -18.0 |
| Net margin | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | |
| |
| Diluted EPS | ($3.71) | $0.72 | ($2.24) | ($1.93) | ($1.43) | ($13.66) | ($5.33) |
| Shares outstanding (diluted) | 72.0 | 74.0 | 54.8 | 43.8 | 34.6 | 3.9 | 3.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|